Predictors of abnormal involuntary movement in an African schizophrenia population

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 20, Issue 3, 2008, Pages 317-326

  Niehaus, Dana J H ^a,b   Du Plessis, Stan A ^b   Koen, Liezl ^a   Lategan, Barbara H ^a   Steyn, Janus ^a   Oosthuizen, Petrus P ^a   Warnich, Louise ^b   Emsley, Robin A ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ANHEDONIA; ARTICLE; CANNABIS ADDICTION; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; HANDEDNESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SMOKING; SOUTH AFRICA; SUBSTANCE ABUSE;

EID: 52649155138     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2008.20.3.317     Document Type: Article

References (37)

1. Gervin M, Browne S, Lane A, et al: Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 1998; 155:1202-1206
2. Altamura AC, Cavallaro R, Regazzetti MG: Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. Eur Arch Psychiatry Clin Neurosci 1990; 240:9-12
3. Patterson BD, Swingler D, Willows S: Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res 2005; 76:89-97
4. Holden TJ: Tardive dyskinesia in long-term hospitalised Zulu psychiatric patients: a prevalence study. S Afr Med J 1987; 71:88-90
5. Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487
6. Gatere N, Othieno CJ, Kathuku DM: Prevalence of tardive dyskinesia among psychiatric in-patients at Mathari Hospital, Nairobi. East Afr Med J 2002; 79:547-549
7. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N: Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64:1075-1080
8. Guy W, Ban TA, Wilson WH: The prevalence of abnormal involuntary movements among chronic schizophrenics. Int Clin Psychopharmacol 1986; 1:134-144
9. Rittmannsberger H, Schony W: [Prevalence of tardive dyskinesia in long-term hospitalized schizophrenic patients]. Nervenarzt 1986; 57:116-118 (German)
10. Caligiuri MP, Lacro JP, Rockwell E, et al: Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997; 171:148-153
11. Waddington JL, Youssef HA: An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry 1986; 143:1162-1165
12. Waddington JL: Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int Rev Neurobiol 1989; 31:297-353
13. Fenton WS: Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61:S10-14
14. van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG: Tardive dyskinesia in psychosis: are women really more at risk? UK700. Group Acta Psychiatr Scand 1999; 99:288-293
15. Dixon L, Weiden PJ, Haas G, et al: Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Compr Psychiatry 1992; 33:121-122
16. Zaretsky A, Rector NA, Seeman MV, et al: Current cannabis use and tardive dyskinesia. Schizophr Res 1993; 11:3-8
17. Chen EY, Lam LC, Chen RY, et al: Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br J Psychiatry 1996; 168:227-233
18. Brown KW, White T: The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol Psychiatry 1991; 30:1182-1190
19. Liddle PF, Barnes TR, Speller J, et al: Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry 1993; 163:776-780
20. Bartzokis G, Hill MA, Altshuler L, et al: Tardive dyskinesia in schizophrenic patients: correlation with negative symptoms. Psychiatry Res 1989; 28:145-151
21. Chiu H, Lau J, Lam L, et al: Association of negative symptoms with tardive dyskinesia in schizophrenic patients. Aust N Z J Psychiatry 1993; 27:228-232
22. Glazer WM, Morgenstern H, Doucette J: Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry 1994; 45:38-42
23. Niehaus DJ, Koen L, Laurent C, et al: Positive and negative symptoms in affected sib pairs with schizophrenia: implications for genetic studies in an African Xhosa sample. Schizophr Res 2005; 79:239-249
24. Nurnberger JI Jr, Blehar MC, Kaufmann CA, et al: Diagnostic interview for genetic studies: rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51:849-859
25. Guy W: Abnormal Involuntary Movement Scale (AIMS). Washington, DC, Department of Health and Human Services, 1976, pp 534-537
26. Morgenstern H, Glazer WM: Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale tardive dyskinesia study. Arch Gen Psychiatry 1993; 50:723-733
27. Peng C-YJ, So TH: Logistic regression analysis and reporting: a primer. Understanding Statistics 2002; 1:31-70
28. Nocerino E, Amato M, Izzo AA: Cannabis and cannabinoid receptors. Fitoterapia 2000; 71S:S6-12
29. Ujike H, Morita Y: New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004; 96:376-381
30. Dean B, Bradbury R, Copolov DL: Cannabis-sensitive dopaminergic markers in postmortem central nervous system: changes in schizophrenia. Biol Psychiatry 2003; 53:585-592
31. Leweke FM, Giuffrida A, Wurster U, et al: Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10:1665-1669
32. Muller-Vahl KR: Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin Pharmacother 2003; 4:1717-1725
33. Schneider U, Leweke FM, Mueller-Vahl KR, et al: Cannabinoid/anandamide system and schizophrenia: is there evidence for association? Pharmacopsychiatry 1998; 31:S110-113
34. Matsuda LA, Bonner TI, Lolait SJ: Cannabinoid receptors: which cells, where, how, and why? NIDA Res Monogr 1992; 126:48-56
35. Brown KW, White T: Sub-syndromes of tardive dyskinesia and some clinical correlates. Psychol Med 1992; 22:923-927
36. Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159:1642-1652
37. Fox SH, Kellett M, Moore AP, et al: Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002; 17:145-149